Execs On The Move: April 2023
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
You may also be interested in...
Investor Eye: A Licensing-Based Approach May Be Best For Revolutionary IP
Keeping a firm grip on one’s IP is a cornerstone of most innovative businesses. However, Robert Cote, CEO of Cote Capital, believes that if the idea is good enough to keep close, it’s good enough to license out.
The Illumina Shareholder Votes Are In, And Nobody Got What They Wanted
Carl Icahn was successful in ousting Illumina’s chair, however its CEO, Francis deSouza remains. Both analysts and investors believe this could further encourage Illumina to divest Grail.
Swedish Drug And Device To Go Head-To-Head In The GERD Space
Two Swedish companies are working on tackling GERD – one with a drug, one with a device.